Immutep's First-in-Class LAG-3 Agonist Shows Promising Immunosuppressive Effects in Phase I Autoimmune Disease Trial
核心洞察
Immutep's IMP761, a first-in-class LAG-3 (搜索) agonist antibody, demonstrated dose-dependent immunosuppressive effects with significant T-cell inhibition lasting up to 23 days in a Phase I study.
The single-ascending dose trial successfully completed 2.5 and 7 mg/kg dosing levels with favorable safety profile and no treatment-related adverse reactions beyond mild intensity.
IMP761 targets the LAG-3 (搜索) immune checkpoint to silence dysregulated T cells, potentially addressing the root cause of autoimmune diseases (搜索) including rheumatoid arthritis (搜索), Type 1 diabetes (搜索), and multiple sclerosis (搜索).
Immutep Limited (搜索) has announced positive interim results from its Phase I study of IMP761, a first-in-class LAG-3 (搜索) agonist antibody designed to treat autoimmune diseases (搜索). The placebo-controlled, double-blind first-in-human study in healthy participants demonstrated encouraging safety and efficacy signals that could represent a breakthrough in autoimmune disease treatment.
Dose-Dependent Immunosuppressive Activity Observed
The single-ascending dose escalation portion of the trial successfully completed the 2.5 and 7 mg/kg dosing levels of IMP761 with continued positive safety and efficacy data. Most notably, the study revealed evidence of dose-dependent immunosuppressive effects with significant, long-lasting inhibition of three T-cell-mediated intradermal reactions to a strong foreign antigen at days 2, 9, and 23.
IMP761 was well tolerated with no treatment-related adverse reactions beyond mild intensity, establishing a favorable safety profile for this novel therapeutic approach.
Dr. Frédéric Triebel, Chief Scientific Officer of Immutep, emphasized the significance of these findings: "We are excited to see IMP761 having a long-term immunosuppressive effect after a single injection. A solid pharmacokinetic/pharmacodynamic relationship has now been established between 1 and 7 mg/kg with eight participants per group to cover the variability of the responses."
Novel Mechanism Targets Root Cause of Autoimmune Disease
IMP761 represents the first LAG-3 (搜索) agonist antibody developed to potentially treat autoimmune diseases (搜索) by enhancing the "brake" function of LAG-3 to silence dysregulated self-antigen-specific memory T cells. This approach is designed to target the cause of autoimmune diseases and restore balance to the immune system.
The LAG-3 (搜索) (lymphocyte-activation gene-3) immune checkpoint has been identified as a promising therapeutic target for many autoimmune diseases (搜索), including rheumatoid arthritis (搜索), Type 1 diabetes (搜索), and multiple sclerosis (搜索). LAG-3 expression on activated T cells demonstrates high specificity for disease sites, especially in regions characterized by chronic inflammation.
This distinct characteristic of the LAG-3 (搜索) immune checkpoint suggests IMP761 may enable a more targeted therapeutic approach with fewer adverse effects compared to other treatments currently available for autoimmune conditions.
Substantial Market Opportunity and Clinical Development Path
IMP761 is positioned to address large, increasingly prevalent autoimmune disorders, each of which represents multi-billion dollar markets. The novel immunotherapy's significant level of immune suppression combined with its favorable safety profile provides proof-of-concept data in its potential to silence the dysregulated T cells at the epicenter of many autoimmune diseases (搜索).
Triebel noted that "encouragingly, our clinical progress with IMP761 has corresponded with increased external interest in this program," suggesting growing industry recognition of the therapeutic potential.
Preclinical Foundation and Future Development
The clinical progress builds on encouraging preclinical studies published in the Journal of Immunology, which showed IMP761 inhibits peptide-induced T cell proliferation, activation of human primary T cells, and an antigen-specific delayed-type hypersensitivity reaction. Additional preclinical data in oligoarticular juvenile idiopathic arthritis (搜索) published in Pediatric Research demonstrated that IMP761 led to a decrease in a broad spectrum of effector cytokines.
Given the encouraging efficacy and safety data to date, the trial will continue as planned. Additional updates are anticipated in the first half of 2026, including a potential presentation of data at a major medical conference in the field of autoimmune diseases (搜索).